Zevra Therapeutics (ZVRA) News Today $8.00 +0.36 (+4.71%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$8.01 +0.01 (+0.12%) As of 05/2/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $22.29May 4 at 1:07 AM | americanbankingnews.comBarclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Barclays PLC raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 402.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 289,688 shares of the company's stock after purchasing an additionalMay 3 at 3:39 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating toMay 3 at 1:11 AM | marketbeat.com85,818 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by Boothbay Fund Management LLCBoothbay Fund Management LLC bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 85,818 shares of the company's stock, valued at approximateMay 2 at 5:12 AM | marketbeat.comZevra Therapeutics to Participate in the Citizens Life Science ConferenceMay 1, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Nantahala Capital Management LLCNantahala Capital Management LLC reduced its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 20.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,340,333 shares of the company's stock after sApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Adage Capital Partners GP L.L.C. raised its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 462.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,650,000 shares of the company's stockApril 28, 2025 | marketbeat.comGeode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Geode Capital Management LLC boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 13.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,188,120 shares of the company's stock after buying aApril 26, 2025 | marketbeat.comDiadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Diadema Partners LP acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 42,081 shares of the company's stock,April 24, 2025 | marketbeat.comZevra Files Definitive Proxy Statement and Mails Letter to StockholdersApril 21, 2025 | finance.yahoo.comZevra Therapeutics urges stockholders to vote for director nomineesApril 21, 2025 | markets.businessinsider.comZevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest ConcernsApril 21, 2025 | quiverquant.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Boosted by Altium Capital Management LLCAltium Capital Management LLC increased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 8.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,850,000 shares of the company's stock after purchasing an addiApril 19, 2025 | marketbeat.comZevra Therapeutics announces publication on arimoclomolApril 18, 2025 | markets.businessinsider.comZevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and MetabolismApril 17, 2025 | globenewswire.comVanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Vanguard Group Inc. boosted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,824,212 shares of tApril 17, 2025 | marketbeat.comZevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionApril 7, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by BrokeragesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned an average rating of "Buy" from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on tApril 7, 2025 | marketbeat.comZevra Therapeutics: Mixed Feelings On Miplyffa ApprovalApril 3, 2025 | seekingalpha.comZevra Therapeutics Files Preliminary ProxyMarch 31, 2025 | globenewswire.comAIGH Capital Management LLC Invests $6.58 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)AIGH Capital Management LLC acquired a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 788,614 shares of the company's stock, valuMarch 31, 2025 | marketbeat.comZevra Therapeutics management to meet with Cantor FitzgeraldMarch 26, 2025 | markets.businessinsider.comBank of New York Mellon Corp Sells 37,365 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Bank of New York Mellon Corp reduced its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 108,487 shares of the company's stock afterMarch 26, 2025 | marketbeat.comZevra Therapeutics Independent Director Acquires 33% More StockMarch 23, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode Acquires 10,000 SharesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) Director John B. Bode acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average cost of $7.96 per share, with a total value of $79,600.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $318,400. The trade was a 33.33 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.March 22, 2025 | marketbeat.comInsider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of StockMarch 22, 2025 | insidertrades.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on ThursdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670457)March 20, 2025 | marketbeat.comHC Wainwright Predicts Lower Earnings for Zevra TherapeuticsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for Zevra Therapeutics in a report released on Thursday, March 13th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings perMarch 17, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for ZVRA FY2025 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.24) per shareMarch 15, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ZVRA Q1 Earnings?Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Zevra Therapeutics in a research note issued on Thursday, March 13th. HC Wainwright analyst O. Livnat forecasts that the company will earn ($0.23) per shaMarch 15, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q1 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Roth Capital upped their Q1 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report released on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share ofMarch 15, 2025 | marketbeat.comWilliam Blair Brokers Increase Earnings Estimates for ZVRAZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair raised their Q1 2025 earnings estimates for Zevra Therapeutics in a report released on Wednesday, March 12th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.24) per share for the quartMarch 15, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00Canaccord Genuity Group increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday.March 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Expected to Rise, Guggenheim Analyst SaysGuggenheim raised their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday.March 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA FY2029 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Roth Capital lowered their FY2029 earnings estimates for Zevra Therapeutics in a report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.05 foMarch 14, 2025 | marketbeat.comZevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2025 | finance.yahoo.comZevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comZevra Therapeutics’ Earnings Call Highlights Success and GrowthMarch 12, 2025 | tipranks.comZevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Misses Expectations By $0.28 EPSZevra Therapeutics (NASDAQ:ZVRA - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.March 12, 2025 | marketbeat.comZevra Therapeutics: Zevra Reports Full Year 2024 and Fourth Quarter Financial ResultsMarch 12, 2025 | finanznachrichten.deZevra Therapeutics price target raised to $18 from $17 at Citizens JMPMarch 12, 2025 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on Zevra Therapeutics (ZVRA)March 12, 2025 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Buy" by AnalystsShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to thMarch 12, 2025 | marketbeat.comZevra Therapeutics Reports 2024 Financial Results and Strategic ProgressMarch 12, 2025 | tipranks.comZevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comZevra Reports Full Year 2024 and Fourth Quarter Financial ResultsMarch 11, 2025 | globenewswire.comZevra Therapeutics FY 2024 Earnings PreviewMarch 10, 2025 | msn.comInvesting in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gainMarch 4, 2025 | finance.yahoo.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVRA Media Mentions By Week ZVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼1.110.73▲Average Medical News Sentiment ZVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼73▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Agios Pharmaceuticals News Harmony Biosciences News Disc Medicine News Indivior News Vera Therapeutics News ANI Pharmaceuticals News Structure Therapeutics News Mesoblast News Immunocore News Evotec News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
